New Soluble Markers for Assessment of Infarct Size

Al-Saady, N.; Camm, A. John

doi:10.1007/978-94-017-2380-0_12

Cited by 7 publications

(4 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, the measurement of cardiac constituents, such as cardiac enzymes and proteins, is frequently used as a rough estimate of the extent of myocardial damage (27,28). The most important shortcoming in the estimation of infarct size with the cytoplasmatic enzymes such as CK or CKMB and lactate (LDH) or hydroxybutyrate dehydrogenase (HBDH) is the need for serial measurements in order to identify peak or cumulative serum concentrations.…”

Section: Estimation Of Infarct Sizementioning

confidence: 99%

Relative Role of NT-pro BNP and Cardiac Troponin T at 96 hours for Estimation of Infarct Size and Left Ventricular Function After Acute Myocardial Infarction

Steen¹,

Futterer²,

Merten³

et al. 2007

J. of Cardiovascular Magnetic Resonance

View full text Add to dashboard Cite

show abstract

Section: Estimation Of Infarct Sizementioning

confidence: 99%

Relative Role of NT-pro BNP and Cardiac Troponin T at 96 hours for Estimation of Infarct Size and Left Ventricular Function After Acute Myocardial Infarction

Steen¹,

Futterer²,

Merten³

et al. 2007

J. of Cardiovascular Magnetic Resonance

View full text Add to dashboard Cite

show abstract

“…Cardiac biomarkers such as CK-MB and different types of cardiac troponins have gained increasing utility due to their ability in the diagnosis, stratification and also prediction of patients` outcome following acute coronary syndromes ( 29 - 31 ). There is convincing evidence from several trials that CK-MB and cardiac troponins I and/or T are also useful for rough estimation of the extent of myocardial damage ( 8 - 10 , 32 - 34 ). The major limitation of cytoplasmic enzymes such as CK or CK-MB in the estimation of infarct size is the need for serial measurements to identify peak or cumulative serum concentrations.…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome is associated with higher wall motion score and larger infarct size after acute myocardial infarction

Hajsadeghi¹,

Chitsazan²,

Chitsazan³

et al. 2015

Res Cardiovasc Med

View full text Add to dashboard Cite

Background:Infarct size is an important surrogate end point for early and late mortality after acute myocardial infarction. Despite the high prevalence of metabolic syndrome in patients with atherosclerotic diseases, adequate data are still lacking regarding the extent of myocardial necrosis after acute myocardial infarction in these patients.Objectives:In the present study we aimed to compare myocardial infarction size in patients with metabolic syndrome to those without metabolic syndrome using peak CK-MB and cardiac troponin I (cTnI) at 72 hours after the onset of symptoms.Patients and Methods:One-hundred patients with metabolic syndrome (group I) and 100 control subjects without metabolic syndrome (group II) who experienced acute myocardial infarction were included in the study. Diagnosis of metabolic syndrome was based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines published in 2001. Myocardial infarction size was compared between the two groups of patients using peak CK-MB and cTnI level in 72 hours after the onset of symptoms.Results:Peak CK-MB and cTnI in 72 hours were found to be significantly higher in patients with metabolic syndrome compared with control subjects (both P < 0.001). Patients with metabolic syndrome also had markedly higher wall motion abnormality at 72 hours after the onset of symptoms as assessed by echocardiographically-derived Wall Motion Score Index (WMSI) (P < 0.001). Moreover, statistically significant relationships were found between WMSI and peak CK-MB and also cTnI at 72 hours (Spearman's rho = 0.56, P < 0.001 and Spearman's rho = 0.5, P < 0.001; respectively). However, association between WMSI and left ventricular ejection fraction was insignificant (Spearman's rho = -0.05, P = 0.46).Conclusions:We showed that patients with metabolic syndrome have larger infarct size compared to control subjects.

show abstract

“…Cardiac biomarkers such as CK-MB and different types of cardiac troponins have gained increasing utility due to their ability in the diagnosis, stratification and also prediction of patients` outcome following acute coronary syndromes (29)(30)(31). There is convincing evidence from several trials that CK-MB and cardiac troponins I and/or T are also useful for rough estimation of the extent of myocardial damage (8)(9)(10)(32)(33)(34). The major limitation of cytoplasmic enzymes such as CK or CK-MB in the estimation of infarct size is the need for serial measurements to identify peak or cumulative serum concentrations.…”

Section: Discussionmentioning

confidence: 99%

Metabolic syndrome is associated with higher wall motion score and larger infarct size after acute myocardial infarction

Chitsazan¹,

Hajsadeghi²,

Chitsazan³

et al. 2015

Res Cardiovasc Med

View full text Add to dashboard Cite

Background:Infarct size is an important surrogate end point for early and late mortality after acute myocardial infarction. Despite the high prevalence of metabolic syndrome in patients with atherosclerotic diseases, adequate data are still lacking regarding the extent of myocardial necrosis after acute myocardial infarction in these patients. Objectives: In the present study we aimed to compare myocardial infarction size in patients with metabolic syndrome to those without metabolic syndrome using peak CK-MB and cardiac troponin I (cTnI) at 72 hours after the onset of symptoms. Patients and Methods: One-hundred patients with metabolic syndrome (group I) and 100 control subjects without metabolic syndrome (group II) who experienced acute myocardial infarction were included in the study. Diagnosis of metabolic syndrome was based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines published in 2001. Myocardial infarction size was compared between the two groups of patients using peak CK-MB and cTnI level in 72 hours after the onset of symptoms. Results: Peak CK-MB and cTnI in 72 hours were found to be significantly higher in patients with metabolic syndrome compared with control subjects (both P < 0.001). Patients with metabolic syndrome also had markedly higher wall motion abnormality at 72 hours after the onset of symptoms as assessed by echocardiographically-derived Wall Motion Score Index (WMSI) (P < 0.001). Moreover, statistically significant relationships were found between WMSI and peak CK-MB and also cTnI at 72 hours (Spearman's rho = 0.56, P < 0.001 and Spearman's rho = 0.5, P < 0.001; respectively). However, association between WMSI and left ventricular ejection fraction was insignificant (Spearman's rho = -0.05, P = 0.46). Conclusions:We showed that patients with metabolic syndrome have larger infarct size compared to control subjects.

show abstract

New Soluble Markers for Assessment of Infarct Size

Cited by 7 publications

References 73 publications

Relative Role of NT-pro BNP and Cardiac Troponin T at 96 hours for Estimation of Infarct Size and Left Ventricular Function After Acute Myocardial Infarction

Relative Role of NT-pro BNP and Cardiac Troponin T at 96 hours for Estimation of Infarct Size and Left Ventricular Function After Acute Myocardial Infarction

Metabolic syndrome is associated with higher wall motion score and larger infarct size after acute myocardial infarction

Metabolic syndrome is associated with higher wall motion score and larger infarct size after acute myocardial infarction

Contact Info

Product

Resources

About